SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following a reported test setback where its Neutron rocket's Stage 1 tank ruptured during qualification trials. This development has led to market volatility, with a divided community either 'buying the dip' on confidence in defense contracts and future launches, or expressing caution over valuation and anticipating further price declines. Discussion remains intense as investors weigh short-term challenges against the company's long-term potential in the burgeoning space sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community keenly watches significant regulatory developments, including modernized deep-sea mining permit processes from NOAA and an upcoming Congressional hearing featuring the CEO. This activity is fueled by a growing recognition of deep-sea minerals as a national security priority and strong market expectations for accelerated project timelines.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is significantly trending after announcing a favorable arbitration award against Repsol, validating its operational conduct regarding Calcasieu Pass LNG sales. This pivotal win has fueled intense bullish sentiment, with the community actively discussing a potential substantial short squeeze and a strong stock rebound. Many foresee continued upside, driven by the company's execution and persistent global demand for LNG.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by recent analyst upgrades, robust server CPU demand, and growing optimism for its advanced 18A process technology and Panther Lake processors. The community is actively discussing massive gains and long-term potential fueled by strategic government backing, though some anticipate a "sell the news" reaction as investors await the upcoming earnings report.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to significant insider buying, with CEO Ryan Cohen substantially increasing his stake over consecutive days, joined by another board member. This show of conviction is fueling community speculation about a potential short squeeze and a "bottom" being found, reminiscent of past meme stock events. Many are discussing this as a direct challenge to short sellers and a strategic move by management.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending as its dedicated community relentlessly builds a "permissionless brand" with tangible real-world products and ongoing initiatives, from Kendu Spice to entertainment. This active, 'delulu' community emphasizes a long-term vision, consistent development across various blockchains, and a unique commitment to creating lasting value beyond typical crypto hype. The collective effort and daily progress continue to drive robust discussion and conviction among its supporters.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is experiencing extreme volatility and a surge in trading volume following news that its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development, coupled with its notably low share float and recent reverse split, has ignited intense speculative trading, leading many to label it a prime short squeeze candidate. While some foresee substantial further gains, others remain cautious, warning of a potential pump and dump scenario amidst reports of heavy selling pressure.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a significant surge, driven by impressive long-term data from its personalized cancer vaccine candidate in partnership with Merck, demonstrating sustained efficacy against high-risk melanoma. This breakthrough is igniting widespread community discussion about a substantial short squeeze and the company's valuation, as investors anticipate the transformative potential of its mRNA pipeline beyond prior vaccine successes.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Fueling intense debate, Sandisk ($SNDK) is experiencing a historic surge, largely attributed to robust demand for memory and data storage driven by AI infrastructure and tight supply conditions. Community sentiment is bifurcated, with bulls reveling in its "unstoppable" trajectory and a potential short squeeze, while bears warn of an unsustainable "bubble" and impending correction given its extraordinary valuation.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to rumors of a potential acquisition by Zydus Lifesciences, amplified by recent positive updates including a significant patent extension to 2041 for its key therapies and bullish revenue guidance for IBSRELA. The community is actively discussing valuation, believing the company is fundamentally undervalued given its strengthened intellectual property and expanding market potential for its approved drugs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are currently covering the firm, MarketBeat...

The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy

The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $67.00 price objective on the stock in a research report on Monday...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2% - Here's What Happened

Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 8.2% - Here's Why...

Morgan Stanley Increases Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $80.00

Morgan Stanley upped their price target on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an "overweight" rating in a report on Tuesday...

<ul class="summary-bullets"><li>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.</li><li>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates."</li><li>Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</li></ul><p>Crinetics Pharmaceuticals, Inc. (CRNX) said on Monday that its experimental drug Atumelnant yielded positive results in the fourth cohort of a congenital adrenal hyperplasia trial (CAH), sending shares up 3% in Monday’s mid-day trading. &nbsp;</p><p>Atumelnant is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic congenital adrenal hyperplasia as well as adrenocorticotropic hormone-dependent Cushing’s syndrome.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3212693/0/en/Crinetics-Announces-Strong-PALSONIFY-Launch-Execution-and-Positive-Results-for-Concurrent-Androstenedione-Lowering-and-Glucocorticoid-Dose-Reduction-in-Phase-2-Trial-of-Atumelnant-.html?_gl=1*dclqt*_up*MQ..*_ga*MTQ5MTU3MjU2MS4xNzY3NjMzMDE2*_ga_ERWPGTJ5X8*czE3Njc2MzMwMTUkbzEkZzAkdDE3Njc2MzMwMjIkajUzJGwwJGgw">said</a> that treatment with Atumelnant resulted in rapid, sustained lowering of androstenedione in all eight patients that completed the fourth cohort of the mid-stage trial.</p><p>Shares of Neurocrine Biosciences (NBIX), whose Crenessity drug is approved for CAH, fell by 3% following the rival’s update.</p><h2 class="st-heading-2">Trial Results</h2><p>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with CAH caused by 21-hydroxylase deficiency. CAH is a group of genetic disorders affecting the adrenal glands, preventing them from producing enough cortisol and aldosterone. It leads to issues with energy, blood sugar, blood pressure, salt/water balance, and sexual development.</p><p>The drug was observed to be well-tolerated, with no serious adverse events and no treatment-related severe adverse events, the company added.</p><h2 class="st-heading-2">Positive Feedback For Palsonify</h2><p>Separately, Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</p><p>Palsonify was approved by the U.S. Food and Drug Administration (FDA) on September 25 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.</p><p>The company noted that feedback from patients, physicians and payers have been positive thus far.</p><h2 class="st-heading-2">Expert Take</h2><p>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates," as per TheFly.</p><p>The firm believes the Atumelnant update will be "much more impactful" for the stock today as it contends that Crinetics "again looks to comfortably have 2 blockbuster," high odds of success products and more in earlier development.</p><p>RBC Capital analyst Brian Abrahams noted that the data looked very supportive of the drug's ability to be a potential competitor that could reach the CAH market within the next few years, according to TheFly. However, the firm believes comparing the dataset to Neurocrine's phase III study data is limited, primarily due to the differences in patient population. Overall, RBC notes that while competitor data reaffirms a potential emerging player in the CAH space, this was already well known, patient stickiness may shield Crenessity from future competition. Even with conservative estimates, it sees Crenessity contributing $1.1 billion to Neurocrine's revenue stream in the U.S. market alone.</p><p>RBC added that it would be a buyer of Outperform-rated Neurocrine on weakness.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CRNX stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/NBIX">NBIX stock</a> stayed within the ‘bearish’ territory in the same time.</p><p><a href="https://stocktwits.com/symbol/CRNX">CRNX stock</a> has dropped 5% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-q4-deliveries-dive-on-lower-ev-sales/cmxMtAZR4RJ">General Motors Q4 Deliveries Dive On Lower EV Sales — Automaker Looks To Next-Generation Bolt EV For Bounceback</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.

Equity

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High - Still a Buy?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 52-Week High - Should You Buy...

Crinetics Pharmaceuticals touts $5M Palsonify Q4 launch, posts strong atumelnant phase 2 CAH data

Crinetics Pharmaceuticals (NASDAQ:CRNX) provided a corporate update highlighting early commercial progress for Palsonify in acromegaly and new phase 2 data for atumelnant in congenital adrenal...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen

Wall Street Zen raised Crinetics Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Moody Aldrich Partners LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX

Moody Aldrich Partners LLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 16.1% in the third quarter, according to its most recent filing with the SEC. The...

174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the 3rd quarter, according to the company in its most recent...

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.34	--	--	N/A
Q3 '25	-$1.24	-$1.38	-10.90%	MISSED
Q2 '25	-$1.08	-$1.23	-13.73%	MISSED
Q1 '25	-$0.94	-$1.04	-10.54%	MISSED
Q4 '24	-$0.89	-$0.88	0.69%	BEAT

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc